Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects

J Drugs Dermatol. 2023 Dec 1;22(12):e42-e43. doi: 10.36849/JDD.6532.


Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis.  J Drugs Dermatol. 2023;22(12):e42-e43.     doi:10.36849/JDD.6532e.

Publication types

  • Editorial

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • SARS-CoV-2
  • Skin Diseases* / drug therapy


  • tocilizumab